fluphenazine enanthate has been researched along with fluphenazine depot in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Yale, HL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Goude, F; Lanza, JP; Lanza, M | 1 |
| Domino, EF | 1 |
| Altamura, AC; Curry, SH; Montgomery, S; Wiles, DH | 1 |
| Chouinard, G; Cohen, BM; Jones, B; Sommer, BR; Waternaux, C | 1 |
| Annable, L; Chouinard, G; Ross-Chouinard, A | 1 |
| Awad, AG; Hogan, TP | 1 |
| Glazer, WM | 1 |
| Kane, JM | 1 |
| Furukawa, T; Yamada, K | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Den, R; Mimura, M; Sakurai, H; Suzuki, T; Tsutsumi, C; Uchida, H; Uchida, T | 1 |
| Adams, CE; Asher, R; David, A; Eisenbruch, M; Jayaswal, A; Maayan, N; Quraishi, SN; Rathbone, J | 1 |
| Imai, T; Nakada, Y; Ohura, K | 1 |
3 review(s) available for fluphenazine enanthate and fluphenazine depot
| Article | Year |
|---|---|
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Injections, Intramuscular; Male; Patient Compliance; Psychotic Disorders; Receptors, Dopamine; Research Design; Risk; Schizophrenia; Schizophrenic Psychology | 1984 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Schedule; Female; Fluphenazine; Humans; Male; Patient Readmission; Placebos; Psychotic Disorders; Recurrence; Schizophrenia; Schizophrenic Psychology; United States | 1984 |
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Injections, Intramuscular; Randomized Controlled Trials as Topic; Schizophrenia | 2015 |
4 trial(s) available for fluphenazine enanthate and fluphenazine depot
| Article | Year |
|---|---|
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Topics: Adult; Female; Fluphenazine; Humans; Male; Middle Aged; Prolactin; Schizophrenia | 1985 |
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Random Allocation; Schizophrenia; Schizophrenic Psychology | 1982 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Injections, Intramuscular; Male; Patient Compliance; Psychotic Disorders; Receptors, Dopamine; Research Design; Risk; Schizophrenia; Schizophrenic Psychology | 1984 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Schedule; Female; Fluphenazine; Humans; Male; Patient Readmission; Placebos; Psychotic Disorders; Recurrence; Schizophrenia; Schizophrenic Psychology; United States | 1984 |
11 other study(ies) available for fluphenazine enanthate and fluphenazine depot
| Article | Year |
|---|---|
Esters of 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazieneethanol and related compounds as long-acting antipsychotic agents. Synthesis of the 1-adamantoate, the first crystalline base.
Topics: Adamantane; Animals; Antipsychotic Agents; Avoidance Learning; Crystallization; Delayed-Action Preparations; Female; Fluphenazine; Phenothiazines; Rats; Reaction Time | 1977 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
[Effect of a single dose of some long-acting neuroleptics on the estrus cycle and the mammary gland of the rat].
Topics: Animals; Antipsychotic Agents; Caproates; Estrus; Female; Flupenthixol; Fluphenazine; Mammary Glands, Animal; Organ Size; Ovary; Phenothiazines; Pregnancy; Pseudopregnancy; Rats; Thiazines; Uterus | 1979 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Macaca; Male; Motor Activity; Stereotyped Behavior; Substance Withdrawal Syndrome | 1985 |
Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Topics: Delayed-Action Preparations; Fluphenazine; Humans; Regression Analysis; Schizophrenia | 1985 |
Pharmacotherapy and suicide risk in schizophrenia.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluphenazine; Humans; Male; Risk; Schizophrenia; Suicide | 1983 |
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
Topics: Aminooxyacetic Acid; Animals; Antiparkinson Agents; Catalepsy; Delayed-Action Preparations; Drug Synergism; Enkephalins; Fluphenazine; Haloperidol; Humans; Male; Mice; Mice, Inbred Strains; Receptors, Dopamine | 1982 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Female; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Length of Stay; Male; Microspheres; Middle Aged; Patient Discharge; Proportional Hazards Models; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Combinations; Female; Fluphenazine; Haloperidol; Humans; International Classification of Diseases; Longitudinal Studies; Maintenance Chemotherapy; Male; Medical Records; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Secondary Prevention; Treatment Outcome | 2013 |
Bioconversion and P-gp-Mediated Transport of Depot Fluphenazine Prodrugs after Intramuscular Injection.
Topics: Butyrylcholinesterase; Decanoates; Fluphenazine; Heptanoates; Humans; Injections, Intramuscular; Prodrugs | 2023 |